ARTICLE | Clinical News
Gemcabene: Ph IIb ROYAL-1 started
December 7, 2016 10:31 PM UTC
Gemphire began the double-blind, placebo-controlled, U.S. Phase IIb ROYAL-1 trial to evaluate 600 mg oral gemcabene once daily for 12 weeks in up to 104 patients with LDL-C of ≥100 mg/dL not adequatel...
BCIQ Target Profiles